Jared Young

Title(s) Associate In Residence, Psychiatry
SchoolHealth Sciences
vCardDownload vCard

    Collapse Overview 
    Collapse Overview


    Dr. Young received his BSc. (Hons) in Psychology with Biology and his Ph.D. in Psychopharmacology in the Department of Neuroscience, at the University of Edinburgh, sponsored by the Fujisawa Institute for Neuroscience in Edinburgh. He worked for a year at Organon Laboratories in Scotland prior to his arrival at UCSD to conduct his Post-Doctoral training in 2006. This training was primarily with Profs. Mark Geyer and Dilip Jeste at the Consortium for Translational Research in Neuropsychopharmacology (www.ctrin.org), MIRECC San Diego VA (http://www.mirecc.va.gov/visn22), and the Stein Institute for Research on Aging (www.sira.ucsd.edu) respectively. Dr. Young became a Faculty member in 2009.

    Research Interests

    Dr. Young investigates the molecular biology and neural circuitry underlying behavioral abnormalities occurring in major neuropsychiatric disorders. Debilitating forms of mental illness are prevalent but treatment options for these disorders remain limited. For example, despite the fact that cognitive deficits are a major determinant of impaired function in these patients, there are no approved treatments. Despite molecular and genetic advances, treatment development has not kept pace. One major roadblock for treatment development has been the scarcity of effective cross-species models. Dr. Young uses cutting-edge neuroscience to develop novel and sophisticated cross-species models to identify targetable mechanisms to treat mental illnesses.

    Clinical Focus

    In order to examine the molecular biology and neural circuitry underlying behavioral abnormalities occurring in major neuropsychiatric disorders, we characterize such abnormalities using reverse-translated paradigms. For example, using the human 5-choice continuous performance task (originally developed for mice), we have characterized EEG and fMRI abnormalities that occur in patients with bipolar disorder and schizophrenia, the impact smoking, and smoking cessation, has on attentive properties. By identifying neural mechanisms in patients and healthy subjects, these mechanisms can then be investigated in greater depth using the corresponding animal models.

    Collapse Research 
    Collapse Research Activities and Funding
    Cannabis use and the endocannabinoid system in bipolar disorder
    NIH/NIDA R01DA043535May 1, 2018 - Feb 28, 2023
    Role: Co-Principal Investigator
    Cross-species studies of smoking effects on cognition and neuroinflammation in HIV
    NIH/NIDA R01DA044909Aug 1, 2017 - Jul 31, 2022
    Role: Principal Investigator
    Neurophysiological biomarkers of behavioral dimensions from cross-species paradigms
    NIH/NIMH UH3MH109168Apr 1, 2016 - Jun 30, 2020
    Role: Principal Investigator
    Neurophysiological biomarkers of behavioral dimensions from cross-species paradigms
    NIH/NIMH UH2MH109168Apr 1, 2016 - Mar 31, 2018
    Role: Principal Investigator
    Oxytocin as a therapeutic target for Schizophrenia
    NIH/NIMH R01MH103421Apr 1, 2015 - Mar 31, 2020
    Role: Principal Investigator
    A model organism of brain circuitry and behavioral switching for bipolar disorder
    NIH/NIMH R01MH104344Jul 1, 2014 - Jun 30, 2018
    Role: Principal Investigator
    Alpha 7 nicotinic receptor-mediated enhancement of reinforcement learning
    NIH/NIMH R21MH101579Apr 1, 2014 - Mar 31, 2016
    Role: Principal Investigator
    Visuospatial priming in rats: A novel animal model for Tourette Syndrome
    NIH/NIMH R21MH091571Jul 21, 2010 - Apr 30, 2013
    Role: Principal Investigator
    The rodent continuous performance task: Filling the vigilance translational gap
    NIH/NIMH R21MH085221Jul 7, 2009 - Jun 30, 2012
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Milienne-Petiot M, Higa KK, Grim A, Deben D, Groenink L, Twamley EW, Geyer MA, Young JW. Nicotine improves probabilistic reward learning in wildtype but not alpha7 nAChR null mutants, yet alpha7 nAChR agonists do not improve probabilistic learning. Eur Neuropsychopharmacol. 2018 Nov; 28(11):1217-1231. PMID: 30213668.
      View in: PubMed
    2. MacQueen DA, Minassian A, Kenton JA, Geyer MA, Perry W, Brigman JL, Young JW. Amphetamine improves mouse and human attention in the 5-choice continuous performance test. Neuropharmacology. 2018 08; 138:87-96. PMID: 29859849.
      View in: PubMed
    3. Barnes SA, Young JW, Markou A, Adham N, Gyertyán I, Kiss B. Correction to: The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task. Psychopharmacology (Berl). 2018 05; 235(5):1621. PMID: 29564481.
      View in: PubMed
    4. Bismark AW, Thomas ML, Tarasenko M, Shiluk AL, Rackelmann SY, Young JW, Light GA. Reverse translated and gold standard continuous performance tests predict global cognitive performance in schizophrenia. Transl Psychiatry. 2018 04 12; 8(1):80. PMID: 29643355.
      View in: PubMed
    5. Young JW, Cope ZA, Romoli B, Schrurs E, van Enkhuizen J, Sharp RF, Dulcis D. Mice with reduced DAT levels recreate seasonal-induced switching between states in bipolar disorder. Neuropsychopharmacology. 2018 07; 43(8):1721-1731. PMID: 29520059.
      View in: PubMed
    6. Barnes SA, Young JW, Markou A, Adham N, Gyertyán I, Kiss B. The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task. Psychopharmacology (Berl). 2018 05; 235(5):1403-1414. PMID: 29473089.
      View in: PubMed
    7. MacQueen DA, Young JW, Cope ZA. Cognitive Phenotypes for Biomarker Identification in Mental Illness: Forward and Reverse Translation. Curr Top Behav Neurosci. 2018; 40:111-166. PMID: 29858983.
      View in: PubMed
    8. Young JW, Light GA. Cross-Species Neurophysiological Biomarkers of Attentional Dysfunction in Schizophrenia: Bridging the Translational Gap. Neuropsychopharmacology. 2018 01; 43(1):230-231. PMID: 29192660.
      View in: PubMed
    9. Kwiatkowski MA, Hellemann G, Sugar CA, Cope ZA, Minassian A, Perry W, Geyer MA, Young JW. Dopamine transporter knockdown mice in the behavioral pattern monitor: A robust, reproducible model for mania-relevant behaviors. Pharmacol Biochem Behav. 2017 Dec 28. PMID: 29289701.
      View in: PubMed
    10. Amitai N, Powell SB, Young JW. Phencyclidine increased while isolation rearing did not affect progressive ratio responding in rats: Investigating potential models of amotivation in schizophrenia. Behav Brain Res. 2017 Nov 22. PMID: 29175446.
      View in: PubMed
    11. Minassian A, Young JW, Geyer MA, Kelsoe JR, Perry W. The COMT Val158Met Polymorphism and Exploratory Behavior in Bipolar Mania. Mol Neuropsychiatry. 2018 Feb; 3(3):151-156. PMID: 29594134.
      View in: PubMed
    12. Thaney VE, Sanchez AB, Fields JA, Minassian A, Young JW, Maung R, Kaul M. Transgenic mice expressing HIV-1 envelope protein gp120 in the brain as an animal model in neuroAIDS research. J Neurovirol. 2018 Apr; 24(2):156-167. PMID: 29075998.
      View in: PubMed
    13. MacQueen DA, Minassian A, Henry BL, Geyer MA, Young JW, Perry W. Amphetamine Modestly Improves Conners' Continuous Performance Test Performance in Healthy Adults. J Int Neuropsychol Soc. 2018 Mar; 24(3):283-293. PMID: 29032769.
      View in: PubMed
    14. Milienne-Petiot M, Groenink L, Minassian A, Young JW. Blockade of dopamine D1-family receptors attenuates the mania-like hyperactive, risk-preferring, and high motivation behavioral profile of mice with low dopamine transporter levels. J Psychopharmacol. 2017 10; 31(10):1334-1346. PMID: 28950781.
      View in: PubMed
    15. Cope ZA, Minassian A, Kreitner D, MacQueen DA, Milienne-Petiot M, Geyer MA, Perry W, Young JW. Modafinil improves attentional performance in healthy, non-sleep deprived humans at doses not inducing hyperarousal across species. Neuropharmacology. 2017 Oct; 125:254-262. PMID: 28774856.
      View in: PubMed
    16. Bhakta SG, Young JW. The 5 choice continuous performance test (5C-CPT): A novel tool to assess cognitive control across species. J Neurosci Methods. 2017 Dec 01; 292:53-60. PMID: 28754432.
      View in: PubMed
    17. Barnes SA, Der-Avakian A, Young JW. Preclinical Models to Investigate Mechanisms of Negative Symptoms in Schizophrenia. Schizophr Bull. 2017 07 01; 43(4):706-711. PMID: 28586462.
      View in: PubMed
    18. Bismark AW, Thomas ML, Tarasenko M, Shiluk AL, Rackelmann SY, Young JW, Light GA. Relationship between effortful motivation and neurocognition in schizophrenia. Schizophr Res. 2018 03; 193:69-76. PMID: 28673753.
      View in: PubMed
    19. Pletnikov M, Young JW, Hall FS, Kent S. Introduction to the special issue from the 2015 meeting of the International Behavioral Neuroscience Society. Neurosci Biobehav Rev. 2017 05; 76(Pt B):185-186. PMID: 28300550.
      View in: PubMed
    20. Milienne-Petiot M, Geyer MA, Arnt J, Young JW. Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania. Psychopharmacology (Berl). 2017 03; 234(6):1017-1028. PMID: 28160035.
      View in: PubMed
    21. Higa KK, Young JW, Ji B, Nichols DE, Geyer MA, Zhou X. Striatal dopamine D1 receptor suppression impairs reward-associative learning. Behav Brain Res. 2017 04 14; 323:100-110. PMID: 28143767.
      View in: PubMed
    22. Cope ZA, Young JW. The Five-Choice Continuous Performance Task (5C-CPT): A Cross-Species Relevant Paradigm for Assessment of Vigilance and Response Inhibition in Rodents. Curr Protoc Neurosci. 2017 01 03; 78:9.56.1-9.56.18. PMID: 28046200.
      View in: PubMed
    23. Young JW, Bismark AW, Sun Y, Zhang W, McIlwain M, Grootendorst I, Light GA. Neurophysiological Characterization of Attentional Performance Dysfunction in Schizophrenia Patients in a Reverse-Translated Task. Neuropsychopharmacology. 2017 May; 42(6):1338-1348. PMID: 27917869.
      View in: PubMed
    24. Khan A, de Jong LA, Kamenski ME, Higa KK, Lucero JD, Young JW, Behrens MM, Powell SB. Adolescent GBR12909 exposure induces oxidative stress, disrupts parvalbumin-positive interneurons, and leads to hyperactivity and impulsivity in adult mice. Neuroscience. 2017 03 14; 345:166-175. PMID: 27890827.
      View in: PubMed
    25. Young JW, Winstanley CA, Brady AM, Hall FS. Research Domain Criteria versus DSM V: How does this debate affect attempts to model corticostriatal dysfunction in animals? Neurosci Biobehav Rev. 2017 05; 76(Pt B):301-316. PMID: 27826070.
      View in: PubMed
    26. Milienne-Petiot M, Kesby JP, Graves M, van Enkhuizen J, Semenova S, Minassian A, Markou A, Geyer MA, Young JW. The effects of reduced dopamine transporter function and chronic lithium on motivation, probabilistic learning, and neurochemistry in mice: Modeling bipolar mania. Neuropharmacology. 2017 02; 113(Pt A):260-270. PMID: 27732870.
      View in: PubMed
    27. Cope ZA, Halberstadt AL, van Enkhuizen J, Flynn AD, Breier M, Swerdlow NR, Geyer MA, Young JW. Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challenges. Psychopharmacology (Berl). 2016 10; 233(19-20):3513-25. PMID: 27534540.
      View in: PubMed
    28. Pillidge K, Porter AJ, Young JW, Stanford SC. Perseveration by NK1R-/- ('knockout') mice is blunted by doses of methylphenidate that affect neither other aspects of their cognitive performance nor the behaviour of wild-type mice in the 5-Choice Continuous Performance Test. J Psychopharmacol. 2016 09; 30(9):837-47. PMID: 27097734.
      View in: PubMed
    29. Landgraf D, Joiner WJ, McCarthy MJ, Kiessling S, Barandas R, Young JW, Cermakian N, Welsh DK. The mood stabilizer valproic acid opposes the effects of dopamine on circadian rhythms. Neuropharmacology. 2016 08; 107:262-270. PMID: 27033596.
      View in: PubMed
    30. Halberstadt AL, Sindhunata IS, Scheffers K, Flynn AD, Sharp RF, Geyer MA, Young JW. Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice. Neuropharmacology. 2016 08; 107:364-375. PMID: 27020041.
      View in: PubMed
    31. Higa KK, Young JW, Geyer MA. Wet or dry: translatable "water mazes" for mice and humans. J Clin Invest. 2016 Feb; 126(2):477-9. PMID: 26784538; PMCID: PMC4731183 [Available on 02/01/17].
    32. Young JW, Minassian A, Geyer MA. Locomotor Profiling from Rodents to the Clinic and Back Again. Curr Top Behav Neurosci. 2016; 28:287-303. PMID: 27418071.
      View in: PubMed
    33. Brigman JL, Young JW, Pletnikov M, Kent S. Dispatches from the International Behavioral Neuroscience Society meeting 2014. Introduction. Behav Brain Res. 2015 Dec 15; 295:1-2. PMID: 26549148.
      View in: PubMed
    34. Amitai N, Powell S, Weber M, Swerdlow NR, Young JW. Negative visuospatial priming in isolation-reared rats: Evidence of resistance to the disruptive effects of amphetamine. Cogn Affect Behav Neurosci. 2015 Dec; 15(4):901-14. PMID: 26220402; PMCID: PMC4641795 [Available on 12/01/16].
    35. Porter AJ, Pillidge K, Stanford SC, Young JW. Differences in the performance of NK1R-/- ('knockout') and wildtype mice in the 5-Choice Continuous Performance Test. Behav Brain Res. 2016 Feb 01; 298(Pt B):268-77. PMID: 26522842.
      View in: PubMed
    36. Young JW, Hall FS, Pletnikov M, Kent S. Introduction to the special issue from the 2014 meeting of the International Behavioral Neuroscience Society. Neurosci Biobehav Rev. 2015 Nov; 58:1-3. PMID: 26672720.
      View in: PubMed
    37. Minassian A, Young JW, Cope ZA, Henry BL, Geyer MA, Perry W. Amphetamine increases activity but not exploration in humans and mice. Psychopharmacology (Berl). 2016 Jan; 233(2):225-33. PMID: 26449721.
      View in: PubMed
    38. van Enkhuizen J, Geyer MA, Minassian A, Perry W, Henry BL, Young JW. Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies. Neurosci Biobehav Rev. 2015 Nov; 58:4-18. PMID: 26297513; PMCID: PMC4684462 [Available on 11/01/16].
    39. Horan WP, Reddy LF, Barch DM, Buchanan RW, Dunayevich E, Gold JM, Marder SR, Wynn JK, Young JW, Green MF. Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 2—External Validity and Correlates. Schizophr Bull. 2015 Sep; 41(5):1055-65. PMID: 26209546; PMCID: PMC4535650.
    40. Young JW, Markou A. Translational Rodent Paradigms to Investigate Neuromechanisms Underlying Behaviors Relevant to Amotivation and Altered Reward Processing in Schizophrenia. Schizophr Bull. 2015 Sep; 41(5):1024-34. PMID: 26194891; PMCID: PMC4535652.
    41. van Enkhuizen J, Milienne-Petiot M, Geyer MA, Young JW. Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most, but not all features. Psychopharmacology (Berl). 2015 Sep; 232(18):3455-67. PMID: 26141192; PMCID: PMC4537820.
    42. Reddy LF, Horan WP, Barch DM, Buchanan RW, Dunayevich E, Gold JM, Lyons N, Marder SR, Treadway MT, Wynn JK, Young JW, Green MF. Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms. Schizophr Bull. 2015 Sep; 41(5):1045-54. PMID: 26142081; PMCID: PMC4535649.
    43. Orsini CA, Moorman DE, Young JW, Setlow B, Floresco SB. Neural mechanisms regulating different forms of risk-related decision-making: Insights from animal models. Neurosci Biobehav Rev. 2015 Nov; 58:147-67. PMID: 26072028.
      View in: PubMed
    44. Hall FS, Der-Avakian A, Gould TJ, Markou A, Shoaib M, Young JW. Negative affective states and cognitive impairments in nicotine dependence. Neurosci Biobehav Rev. 2015 Nov; 58:168-85. PMID: 26054790.
      View in: PubMed
    45. Higa KK, Ji B, Buell MR, Risbrough VB, Powell SB, Young JW, Geyer MA, Zhou X. Restoration of Sp4 in Forebrain GABAergic Neurons Rescues Hypersensitivity to Ketamine in Sp4 Hypomorphic Mice. Int J Neuropsychopharmacol. 2015 Jun 02; 18(11):pyv063. PMID: 26037489; PMCID: PMC4756721.
    46. Powell SB, Khan A, Young JW, Scott CN, Buell MR, Caldwell S, Tsan E, de Jong LA, Acheson DT, Lucero J, Geyer MA, Behrens MM. Early Adolescent Emergence of Reversal Learning Impairments in Isolation-Reared Rats. Dev Neurosci. 2015; 37(3):253-62. PMID: 26022788; PMCID: PMC4644772.
    47. Young JW, Kamenski ME, Higa KK, Light GA, Geyer MA, Zhou X. GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders. Neuropsychopharmacology. 2015 Nov; 40(12):2715-26. PMID: 25907107; PMCID: PMC4864647 [Available on 11/01/16].
    48. Young JW, Dulcis D. Investigating the mechanism(s) underlying switching between states in bipolar disorder. Eur J Pharmacol. 2015 Jul 15; 759:151-62. PMID: 25814263; PMCID: PMC4437855.
    49. Young JW, Potter WZ, Riley S, Groeneveld GJ, Kinon BJ, Egan MF, Feltner DE. Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium. Innov Clin Neurosci. 2015 Mar-Apr; 12(3-4):5S-10S. PMID: 25977839; PMCID: PMC4571292.
    50. Kesby JP, Heaton RK, Young JW, Umlauf A, Woods SP, Letendre SL, Markou A, Grant I, Semenova S. Methamphetamine Exposure Combined with HIV-1 Disease or gp120 Expression: Comparison of Learning and Executive Functions in Humans and Mice. Neuropsychopharmacology. 2015 Jul; 40(8):1899-909. PMID: 25652249; PMCID: PMC4839513.
    51. Young JW, Geyer MA. Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J Psychopharmacol. 2015 Feb; 29(2):178-96. PMID: 25516372; PMCID: PMC4670265.
    52. van Enkhuizen J, Janowsky DS, Olivier B, Minassian A, Perry W, Young JW, Geyer MA. The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited. Eur J Pharmacol. 2015 Apr 15; 753:114-26. PMID: 25107282; PMCID: PMC4318788.
    53. van Enkhuizen J, Henry BL, Minassian A, Perry W, Milienne-Petiot M, Higa KK, Geyer MA, Young JW. Reduced dopamine transporter functioning induces high-reward risk-preference consistent with bipolar disorder. Neuropsychopharmacology. 2014 Dec; 39(13):3112-22. PMID: 25005251; PMCID: PMC4229584.
    54. Ji B, Higa KK, Kim M, Zhou L, Young JW, Geyer MA, Zhou X. Inhibition of protein translation by the DISC1-Boymaw fusion gene from a Scottish family with major psychiatric disorders. Hum Mol Genet. 2014 Nov 01; 23(21):5683-705. PMID: 24908665.
      View in: PubMed
    55. Young JW, Ratty A, Dawe GS, Geyer MA. Altered exploration and sensorimotor gating of the chakragati mouse model of schizophrenia. Behav Neurosci. 2014 Aug; 128(4):460-7. PMID: 24708299; PMCID: PMC4107138.
    56. Amitai N, Young JW, Higa K, Sharp RF, Geyer MA, Powell SB. Isolation rearing effects on probabilistic learning and cognitive flexibility in rats. Cogn Affect Behav Neurosci. 2014 Mar; 14(1):388-406. PMID: 23943516; PMCID: PMC3923850.
    57. Henry BL, Geyer MA, Buell MR, Perry W, Young JW, Minassian A. Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine. Behav Pharmacol. 2014 Feb; 25(1):12-22. PMID: 24281153; PMCID: PMC3926694.
    58. van Enkhuizen J, Acheson D, Risbrough V, Drummond S, Geyer MA, Young JW. Sleep deprivation impairs performance in the 5-choice continuous performance test: similarities between humans and mice. Behav Brain Res. 2014 Mar 15; 261:40-8. PMID: 24333377; PMCID: PMC3937379.
    59. van Enkhuizen J, Geyer MA, Halberstadt AL, Zhuang X, Young JW. Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder. J Affect Disord. 2014 Feb; 155:247-54. PMID: 24287168; PMCID: PMC3924859.
    60. Young JW, Geyer MA. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol. 2013 Oct 15; 86(8):1122-32. PMID: 23856289; PMCID: PMC3797190.
    61. Acheson DT, Twamley EW, Young JW. Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development. Front Neurosci. 2013; 7:103. PMID: 23785309.
      View in: PubMed
    62. Ji B, Wang X, Pinto-Duarte A, Kim M, Caldwell S, Young JW, Behrens MM, Sejnowski TJ, Geyer MA, Zhou X. Prolonged Ketamine Effects in Sp4 Hypomorphic Mice: Mimicking Phenotypes of Schizophrenia. PLoS One. 2013; 8(6):e66327. PMID: 23823008.
      View in: PubMed
    63. Henry BL, Minassian A, Patt VM, Hua J, Young JW, Geyer MA, Perry W. Inhibitory deficits in euthymic bipolar disorder patients assessed in the human behavioral pattern monitor. J Affect Disord. 2013 Sep 25; 150(3):948-54. PMID: 23759280; PMCID: PMC3759601.
    64. van Enkhuizen J, Minassian A, Young JW. Further evidence for Clock?19 mice as a model for bipolar disorder mania using cross-species tests of exploration and sensorimotor gating. Behav Brain Res. 2013 Jul 15; 249:44-54. PMID: 23623885; PMCID: PMC3672322.
    65. McKenna BS, Young JW, Dawes SE, Asgaard GL, Eyler LT. Bridging the bench to bedside gap: validation of a reverse-translated rodent continuous performance test using functional magnetic resonance imaging. Psychiatry Res. 2013 Jun 30; 212(3):183-91. PMID: 23570915.
      View in: PubMed
    66. Rissling AJ, Park SH, Young JW, Rissling MB, Sugar CA, Sprock J, Mathias DJ, Pela M, Sharp RF, Braff DL, Light GA. Demand and modality of directed attention modulate "pre-attentive" sensory processes in schizophrenia patients and nonpsychiatric controls. Schizophr Res. 2013 May; 146(1-3):326-35. PMID: 23490760.
      View in: PubMed
    67. Turner KM, Young JW, McGrath JJ, Eyles DW, Burne TH. Cognitive performance and response inhibition in developmentally vitamin D (DVD)-deficient rats. Behav Brain Res. 2013 Apr 01; 242:47-53. PMID: 23275047.
      View in: PubMed
    68. Young JW, Meves JM, Geyer MA. Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behav Brain Res. 2013 Mar 01; 240:119-33. PMID: 23201359; PMCID: PMC3538919.
    69. van Enkhuizen J, Geyer MA, Kooistra K, Young JW. Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice. Int J Neuropsychopharmacol. 2013 Jun; 16(5):1021-31. PMID: 23164454; PMCID: PMC3920978.
    70. Young JW, Jentsch JD, Bussey TJ, Wallace TL, Hutcheson DM. Consideration of species differences in developing novel molecules as cognition enhancers. Neurosci Biobehav Rev. 2013 Nov; 37(9 Pt B):2181-93. PMID: 23064177; PMCID: PMC3594426.
    71. Amitai N, Weber M, Swerdlow NR, Sharp RF, Breier MR, Halberstadt AL, Young JW. A novel visuospatial priming task for rats with relevance to Tourette syndrome and modulation of dopamine levels. Neurosci Biobehav Rev. 2013 Jul; 37(6):1139-49. PMID: 23010529; PMCID: PMC3556379.
    72. van Enkhuizen J, Geyer MA, Young JW. Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling task: relevance to mania. Psychopharmacology (Berl). 2013 Feb; 225(3):661-74. PMID: 22945515; PMCID: PMC3537839.
    73. Henry BL, Geyer MA, Buell M, Perry W, Young JW, Minassian A. Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice. Behav Brain Res. 2013 Jan 01; 236(1):210-20. PMID: 22960458; PMCID: PMC3482284.
    74. Abbs B, Achalia RM, Adelufosi AO, Aktener AY, Beveridge NJ, Bhakta SG, Blackman RK, Bora E, Byun MS, Cabanis M, Carrion R, Castellani CA, Chow TJ, Dmitrzak-Weglarz M, Gayer-Anderson C, Gomes FV, Haut K, Hori H, Kantrowitz JT, Kishimoto T, Lee FH, Lin A, Palaniyappan L, Quan M, Rubio MD, Ruiz de Azúa S, Sahoo S, Strauss GP, Szczepankiewicz A, Thompson AD, Trotta A, Tully LM, Uchida H, Velthorst E, Young JW, O'Shea A, Delisi LE. The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: summaries of oral sessions. Schizophr Res. 2012 Oct; 141(1):e1-e24. PMID: 22910407; PMCID: PMC3877922.
    75. Tanaka S, Young JW, Halberstadt AL, Masten VL, Geyer MA. Four factors underlying mouse behavior in an open field. Behav Brain Res. 2012 Jul 15; 233(1):55-61. PMID: 22569582; PMCID: PMC3866095.
    76. Harms LR, Turner KM, Eyles DW, Young JW, McGrath JJ, Burne TH. Attentional processing in C57BL/6J mice exposed to developmental vitamin D deficiency. PLoS One. 2012; 7(4):e35896. PMID: 22563415; PMCID: PMC3338544.
    77. Gilmour G, Arguello A, Bari A, Brown VJ, Carter C, Floresco SB, Jentsch DJ, Tait DS, Young JW, Robbins TW. Measuring the construct of executive control in schizophrenia: defining and validating translational animal paradigms for discovery research. Neurosci Biobehav Rev. 2013 Nov; 37(9 Pt B):2125-40. PMID: 22548905.
      View in: PubMed
    78. Soontornniyomkij V, Risbrough VB, Young JW, Soontornniyomkij B, Jeste DV, Achim CL. Hippocampal calbindin-1 immunoreactivity correlate of recognition memory performance in aged mice. Neurosci Lett. 2012 May 10; 516(1):161-5. PMID: 22503902; PMCID: PMC3338865.
    79. Brigman JL, Powell EM, Mittleman G, Young JW. Examining the genetic and neural components of cognitive flexibility using mice. Physiol Behav. 2012 Dec 05; 107(5):666-9. PMID: 22234243; PMCID: PMC3337351.
    80. Young JW, Amitai N, Geyer MA. Behavioral animal models to assess pro-cognitive treatments for schizophrenia. Handb Exp Pharmacol. 2012; (213):39-79. PMID: 23027412.
      View in: PubMed
    81. Young JW, Henry BL, Geyer MA. Predictive animal models of mania: hits, misses and future directions. Br J Pharmacol. 2011 Oct; 164(4):1263-84. PMID: 21410454; PMCID: PMC3229761.
    82. Barnes SA, Young JW, Neill JC. D1 receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test. Psychopharmacology (Berl). 2012 Mar; 220(1):129-41. PMID: 21901319.
      View in: PubMed
    83. Minassian A, Henry BL, Young JW, Masten V, Geyer MA, Perry W. Repeated assessment of exploration and novelty seeking in the human behavioral pattern monitor in bipolar disorder patients and healthy individuals. PLoS One. 2011; 6(8):e24185. PMID: 21912623.
      View in: PubMed
    84. Tanaka S, Young JW, Gresack JE, Geyer MA, Risbrough VB. Factor analysis of attentional set-shifting performance in young and aged mice. Behav Brain Funct. 2011 Aug 12; 7:33. PMID: 21838910; PMCID: PMC3174878.
    85. Young JW, Meves JM, Tarantino IS, Caldwell S, Geyer MA. Delayed procedural learning in a7-nicotinic acetylcholine receptor knockout mice. Genes Brain Behav. 2011 Oct; 10(7):720-33. PMID: 21679297; PMCID: PMC3918170.
    86. Young JW, Powell SB, Geyer MA. Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology. 2012 Mar; 62(3):1381-90. PMID: 21726569; PMCID: PMC3217063.
    87. Barnes SA, Young JW, Neill JC. Rats tested after a washout period from sub-chronic PCP administration exhibited impaired performance in the 5-Choice Continuous Performance Test (5C-CPT) when the attentional load was increased. Neuropharmacology. 2012 Mar; 62(3):1432-41. PMID: 21569782.
      View in: PubMed
    88. Young JW, Powell SB, Scott CN, Zhou X, Geyer MA. The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding. Behav Brain Res. 2011 Sep 12; 222(1):183-92. PMID: 21458500; PMCID: PMC3531561.
    89. Soontornniyomkij V, Risbrough VB, Young JW, Soontornniyomkij B, Jeste DV, Achim CL. Increased hippocampal accumulation of autophagosomes predicts short-term recognition memory impairment in aged mice. Age (Dordr). 2012 Apr; 34(2):305-16. PMID: 21431350; PMCID: PMC3312638.
    90. Young JW, van Enkhuizen J, Winstanley CA, Geyer MA. Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania. J Psychopharmacol. 2011 Jul; 25(7):934-43. PMID: 21421642; PMCID: PMC3568506.
    91. Young JW, Kooistra K, Geyer MA. Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil. Neuropsychopharmacology. 2011 Jun; 36(7):1385-96. PMID: 21412225; PMCID: PMC3096808.
    92. Henry BL, Minassian A, van Rhenen M, Young JW, Geyer MA, Perry W. Effect of methamphetamine dependence on inhibitory deficits in a novel human open-field paradigm. Psychopharmacology (Berl). 2011 Jun; 215(4):697-707. PMID: 21279333.
      View in: PubMed
    93. Tarantino IS, Sharp RF, Geyer MA, Meves JM, Young JW. Working memory span capacity improved by a D2 but not D1 receptor family agonist. Behav Brain Res. 2011 Jun 01; 219(2):181-8. PMID: 21232557; PMCID: PMC3073724.
    94. Ali SS, Young JW, Wallace CK, Gresack J, Jeste DV, Geyer MA, Dugan LL, Risbrough VB. Initial evidence linking synaptic superoxide production with poor short-term memory in aged mice. Brain Res. 2011 Jan 12; 1368:65-70. PMID: 21075081; PMCID: PMC3018762.
    95. Minassian A, Young JW. Evaluation of the clinical efficacy of asenapine in schizophrenia. Expert Opin Pharmacother. 2010 Aug; 11(12):2107-15. PMID: 20642375; PMCID: PMC2924192.
    96. Perry W, Minassian A, Henry B, Kincaid M, Young JW, Geyer MA. Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm. Psychiatry Res. 2010 Jun 30; 178(1):84-91. PMID: 20471103; PMCID: PMC2914139.
    97. Young JW, Powell SB, Geyer MA, Jeste DV, Risbrough VB. The mouse attentional-set-shifting task: a method for assaying successful cognitive aging? Cogn Affect Behav Neurosci. 2010 May; 10(2):243-51. PMID: 20498348; PMCID: PMC2877277.
    98. Soontornniyomkij V, Risbrough VB, Young JW, Wallace CK, Soontornniyomkij B, Jeste DV, Achim CL. Short-term recognition memory impairment is associated with decreased expression of FK506 binding protein 51 in the aged mouse brain. Age (Dordr). 2010 Sep; 32(3):309-22. PMID: 20422297; PMCID: PMC2926850.
    99. Henry BL, Minassian A, Young JW, Paulus MP, Geyer MA, Perry W. Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neurosci Biobehav Rev. 2010 Jul; 34(8):1296-306. PMID: 20398694; PMCID: PMC2900445.
    100. Young JW, Goey AK, Minassian A, Perry W, Paulus MP, Geyer MA. The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacol Biochem Behav. 2010 Jul; 96(1):7-15. PMID: 20363246; PMCID: PMC2878916.
    101. Young JW, Geyer MA. Action of modafinil--increased motivation via the dopamine transporter inhibition and D1 receptors? Biol Psychiatry. 2010 Apr 15; 67(8):784-7. PMID: 20132929; PMCID: PMC2849918.
    102. Young JW, Wallace CK, Geyer MA, Risbrough VB. Age-associated improvements in cross-modal prepulse inhibition in mice. Behav Neurosci. 2010 Feb; 124(1):133-140. PMID: 20141288; PMCID: PMC3088993.
    103. Young JW, Zhou X, Geyer MA. Animal models of schizophrenia. Curr Top Behav Neurosci. 2010; 4:391-433. PMID: 21312408.
      View in: PubMed
    104. Minassian A, Henry BL, Geyer MA, Paulus MP, Young JW, Perry W. The quantitative assessment of motor activity in mania and schizophrenia. J Affect Disord. 2010 Jan; 120(1-3):200-6. PMID: 19435640; PMCID: PMC2795051.
    105. Young JW, Goey AK, Minassian A, Perry W, Paulus MP, Geyer MA. GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology (Berl). 2010 Feb; 208(3):443-54. PMID: 20020109; PMCID: PMC2806531.
    106. Perry W, Minassian A, Paulus MP, Young JW, Kincaid MJ, Ferguson EJ, Henry BL, Zhuang X, Masten VL, Sharp RF, Geyer MA. A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry. 2009 Oct; 66(10):1072-80. PMID: 19805697; PMCID: PMC2897252.
    107. Marston HM, Young JW, Martin FD, Serpa KA, Moore CL, Wong EH, Gold L, Meltzer LT, Azar MR, Geyer MA, Shahid M. Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl). 2009 Nov; 206(4):699-714. PMID: 19462162; PMCID: PMC2755103.
    108. Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther. 2009 May; 122(2):150-202. PMID: 19269307; PMCID: PMC2688712.
    109. Young JW. Dopamine D1 and D2 receptor family contributions to modafinil-induced wakefulness. J Neurosci. 2009 Mar 04; 29(9):2663-5. PMID: 19261860; PMCID: PMC2697968.
    110. Young JW, Light GA, Marston HM, Sharp R, Geyer MA. The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One. 2009; 4(1):e4227. PMID: 19156216; PMCID: PMC2626630.
    111. Powell SB, Young JW, Ong JC, Caron MG, Geyer MA. Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behav Pharmacol. 2008 Sep; 19(5-6):562-5. PMID: 18690110; PMCID: PMC2693185.
    112. Young JW, Sharkey J, Finlayson K. Progressive impairment in olfactory working memory in a mouse model of Mild Cognitive Impairment. Neurobiol Aging. 2009 Sep; 30(9):1430-43. PMID: 18242780.
      View in: PubMed
    113. Young JW, Minassian A, Paulus MP, Geyer MA, Perry W. A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev. 2007; 31(6):882-96. PMID: 17706782; PMCID: PMC2025688.
    114. Young JW, Kerr LE, Kelly JS, Marston HM, Spratt C, Finlayson K, Sharkey J. The odour span task: a novel paradigm for assessing working memory in mice. Neuropharmacology. 2007 Feb; 52(2):634-45. PMID: 17097694.
      View in: PubMed
    115. Young JW, Crawford N, Kelly JS, Kerr LE, Marston HM, Spratt C, Finlayson K, Sharkey J. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol. 2007 Jan 15; 17(2):145-55. PMID: 16650968.
      View in: PubMed
    116. Young JW, Finlayson K, Spratt C, Marston HM, Crawford N, Kelly JS, Sharkey J. Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Neuropsychopharmacology. 2004 May; 29(5):891-900. PMID: 14970827.
      View in: PubMed